Table 2.
Genetic predictions and clinical phenotypes related to metabolic and cardiovascular disorders
| Sample ID | Common variant prediction | Clinical phenotype | Clinical risk factors |
|---|---|---|---|
| CHD-1 | T2D (4.5) | - | FMD, CD34+ cells |
| CHD-2 | T2D (3.8); MI (1.24)a | - | BP, N:L ratio, SEVR, HDL-C |
| CHD-3 | Stroke (2.18); CAD (1.21) a; obesity (1.23)b | Obese | Total cholesterol, TG, BP, N:L ratio, FMD, PWV, FRS (CVD) |
| CHD-4 | T2D (1.20); CAD (1.32) a | - | SEVR, N:L ratio, hyperemia, CD34+ cells |
| CHD-5 | CAD (2.09)a; T2D (2.24); stroke (2.18); MI (1.91)a | - | Total cholesterol, LDL-C, SEVR, hyperemia, AIX, PWV |
| CHD-6 | Hypertriglyceridemia (3.48)b; atrial fibrillation (1.35) | Hypertriglyceridemia | HDL-C, SEVR, CD34+ cells |
| CHD-7 | Stroke (2.18)b; MI (1.70); atrial fibrillation (1.35); CAD (1.40) | Stroke | FMD, CD34+ cells |
| CHD-8 | Hypertriglyceridemia (1.72)b; CAD (1.38)a | Hypertriglyceridemia | WHR, glucose, FRS (T2D), total cholesterol, LDL-C, BP, AIX, PWV, FMD |
Abbreviations: AIX: Augmentation Index; BP: blood pressure; CAD: coronary artery disease; CVD: cardiovascular disease; FMD: flow-mediated dilation; FRS: Framingham Risk Scores; HDL: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; MI: myocardial infarction; N:L: neutrophil:lympocyte; SEVR: sub-endocardial viability ratio; T2D: Type 2 diabetes; TG: triglycerides; PWV: pulse wave velocity;. Numbers in brackets indicate LR due to genetic variants. aconcordance with clinical risk factors, bconcordance with clinical phenotype.